Megan T. Sniecinski
2019
In 2019, Megan T. Sniecinski earned a total compensation of $2.2M as Senior Vice President and Chief Business Officer at BioCryst Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $153,000 |
|---|---|
| Option Awards | $1,773,364 |
| Salary | $225,000 |
| Other | $25,590 |
| Total | $2,176,954 |
Sniecinski received $1.8M in option awards, accounting for 81% of the total pay in 2019.
Sniecinski also received $153K in non-equity incentive plan, $225K in salary and $25.6K in other compensation.
Rankings
In 2019, Megan T. Sniecinski's compensation ranked 5,491st out of 13,971 executives tracked by ExecPay. In other words, Sniecinski earned more than 60.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,491 out of 13,971 | 61st |
Division Manufacturing | 2,052 out of 5,701 | 64th |
Major group Chemicals And Allied Products | 729 out of 2,200 | 67th |
Industry group Drugs | 613 out of 1,886 | 68th |
Industry Biological Products, Except Diagnostic Substances | 146 out of 389 | 63rd |
Source: SEC filing on March 31, 2020.
Sniecinski's colleagues
We found four more compensation records of executives who worked with Megan T. Sniecinski at BioCryst Pharmaceuticals in 2019.